Tanabe Pharma America, Inc.

This study looked at two different dosing schedules of an oral medication called edaravone for people with ALS (Lou Gehrig's disease). The goal was to see if one schedule worked better at slowing the disease or delaying death. The study was stopped early, and involved 202 partici…

This study tested an oral form of edaravone in 384 adults with ALS to see if it could slow the disease's progression over 48 weeks. Participants were randomly assigned to different dosing schedules. The trial was terminated early, and results are not yet available.

This early-stage study tested the safety and how the body handles a new drug called MT-6345 in 52 healthy adults. The goal was to see what side effects occur and how the drug moves through the body. Since it was only a safety study in healthy people, there was no treatment for an…